952652-79-8,
(S)-2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)butyramido)-3-methylbutanoic acid,
Despentanoyl butanoyl valsartan,
UNII-4GS9P3LL2L,
4GS9P3LL2L,
[(S-N-BUTYRYL-N-([2'-(1H-TETRAZOLE-5-YL)BIPHEN-4-YL]METHYL)-VALINE),
Valsartan n-Propyl Impurity,
(2S)-2-(Butanoyl((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)amino)-3-methylbutanoic acid,
(S)-2-(N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)butyramido)-3-methylbutanoic acid,
Valsartan related compound B,
(2S)-2-[Butanoyl[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]amino]-3-methylbutanoic Acid,
Valsartan n-Propyl,
Valsartan related compound B [USP],
Valsartan specified impurity C [EP],
Valsartan related compound B RS [USP],
SCHEMBL684206,
CTK8B8225,
DTXSID40241798,
6389AC,
ANW-59704,
SC1425,
ZINC65749016,
ACN-026592,
L-Valine, N-(1-oxobutyl)-N-((2'-(2H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,
AK-40722,
AB0088238,
AX8164353,
TC-148449,
FT-0675774,
ST24035906,
Valsartan Related Compound B, United States Pharmacopeia (USP) Reference Standard,
(2S)-2-[butanoyl-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]-3-methylbutanoic acid,
(2S)-2-[butanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]-3-methylbutanoic acid,
(2S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)butanamido]butanoic acid,
Valsartan Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material,
Valsartan EP Impurity C,
C23H27N5O3,
CB11821,
CS-O-08394,
(S)-N-Butyryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine, 95% - 10MG 10mg,